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Abstract
Background: There are 7000 new cases of head and neck squamous cell cancers (HNSCC) treated by the NHS each
year. Stage III and IV HNSCC can be treated non-surgically by radio therapy (RT) or chemoradiation therapy (CRT).
CRT can affect eating and drinking through a range of side effects with 90 % of patients undergoing this treatment
requiring nutritional support via gastrostomy (G) or nasogastric (NG) tube feeding.
Long-term dysphagia following CRT is a primary concern for patients. The effect of enteral feeding routes on
swallowing function is not well understood, and the two feeding methods have, to date, not been compared to
assess which leads to a better patient outcome.
The purpose of this study is to explore the feasibility of conducting a randomised controlled trial (RCT) comparing
these two options with particular emphasis on patient willingness to be randomised and clinician willingness to
approach eligible patients.
Methods/design: This is a mixed methods multicentre study to establish the feasibility of a randomised controlled
trial comparing oral feeding plus pre-treatment gastrostomy versus oral feeding plus as required nasogastric tube
feeding in patients with HNSCC. A total of 60 participants will be randomised to the two arms of the study (1:1 ratio).
The primary outcome of feasibility is a composite of recruitment (willingness to randomise and be randomised) and
retention. A qualitative process evaluation investigating patient, family and friends and staff experiences of trial
participation will also be conducted alongside an economic modelling exercise to synthesise available evidence and
provide estimates of cost-effectiveness and value of information. Participants will be assessed at baseline
(pre-randomisation), during CRT weekly, 3 months and 6 months.
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Discussion: Clinicians are in equipoise over the enteral feeding options for patients being treated with CRT.
Swallowing outcomes have been identified as a top priority for patients following treatment and this trial would
inform a future larger scale RCT in this area to inform best practice.
Trial registration: ISRCTN48569216
Keywords: Nasogastric tube, Gastrostomy, Swallow outcome, Chemoradiation therapy, Head and neck cancer
Background
Over 7000 new head and neck squamous cell cancers
(HNSCC) are treated by the NHS every year. Patients
with oropharyngeal HNSCC form the major group of
patients who will be eligible for this research project.
The incidence of oropharyngeal cancer in the UK has
more than doubled in the 10 years between 1995 and
2006 [1]. In Scotland, oropharyngeal cancer is the fastest
rising of all cancers [2]. In the USA, it is estimated that
in 2020, oropharyngeal cancer will be more common
than cancer of the uterine cervix [3].
Advanced (stages III and IV) HNSCC are now treated
non-surgically by radiation therapy (RT), or chemoradia-
tion therapy (CRT). In CRT, chemotherapy is delivered
concurrently with RT, potentiating not only tumour kill
but also toxicity, consequently profoundly affecting eat-
ing and drinking by causing a range of side effects: loss
of taste, dry mouth, pain, loss of appetite and impaired
swallow mechanism. Over 90 % of patients receiving this
treatment option need nutritional support for severe
dysphagia and weight loss both during and after treat-
ment. When necessary, nutritional support can be deliv-
ered through a pre-treatment gastrostomy (G) tube or
nasogastric (NG) tube feeds.
Some clinicians advocate that patients with adequate
pre-treatment swallow function and oral intake have pre-
treatment G tubes and continue with oral diet during
treatment until they are no longer able to take adequate
amounts of oral diet to maintain nutritional status. Con-
versely, others offer patients with adequate pre-treatment
swallow function the option of continued oral feeding,
until they are unable to take adequate oral nutrition to
maintain nutritional status and then proceed with (react-
ive) passage of an NG tube as and when necessary [4, 5].
Generic guidance suggests that G tubes should be placed
in patients that need enteral tube feeding for more than
4 weeks [6]. Approximately 2500 gastrostomies are per-
formed for HNSCC patients in the UK. The insertion
costs alone are approximately £3 million per annum.
G-tube placement is an invasive procedure with a small
but defined risk of acute serious complications [7]; 25 to
35 % of patients retain the tube for >1 year after CRT,
10 % >2 years [8], although recent studies show reduced
dependence rates [9] A G-tube has a major impact on pa-
tients’ and carers’ quality of life (QoL) [10, 11], due to
leakage, soiling of clothes, and interference with family
life, intimate relationships and hobbies [12]. While NG
tube placement is relatively simple, the smaller diameter
tube makes it prone to blockage, thus needing repeated
replacement. When care is not taken to ensure correct
placement, NG tube misplacement in the lungs and subse-
quent feeding can lead to significant morbidity, now cate-
gorised as a ‘never event’ by the Department of Health
[13]. Systematic reviews fail to demonstrate evidence for
functional, nutritional, quality of life or health economic
benefit of either approach [14, 15]. UK practice is corres-
pondingly variable and no robust data are available [16].
Both NG and G tube users need community support, with
greater needs for NG tube users. The National Patient
Safety Agency recommends that a full multidisciplinary
supported risk assessment should be made and docu-
mented, before a patient with a nasogastric tube is dis-
charged from acute care to the community. There is
evidence that clinicians in some areas opt for G-tubes due
to barriers to the delivery of NG tube nutritional support
in the community. However, a recent British Society of
Gastroenterology survey showed that only 64 % of G-tube
services offer an aftercare service [17].
Long-term dysphagia is now recognised as the princi-
pal functional consequence of CRT for HNSCC, and pa-
tients report this as a top concern [15, 18]. Dysphagic
patients and those dependent on tube feeds (G and NG
tubes) need significant long-term supportive care and
suffer from impaired quality of life [10]. The effect of ei-
ther enteral feeding route on the swallowing outcome is
not well understood. Gastrostomy placement reduces
the need for the patient undergoing CRT to swallow to
maintain nutrition. Thus, it is likely that patients using
gastrostomy tubes experience a reduction in use of the
swallowing musculature. This reduction combined with
the mucositis caused by radiation has been hypothesised
to increase the risk of fibrosis in the muscles and phar-
yngoesophageal stricture.
The most severe CRT reaction that causes dysphagia
is complete closure of the gullet, devastating for the in-
dividual and with substantial costs for the NHS. While
this risk may be higher with G-tube use, which bypasses
the gullet, unlike an NG tube which maintains a degree
of oesophageal patency, G-tube use is associated with
shorter hospital stay and fewer hospital admissions [19].
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Reconstruction requires complex major reconstructive
surgery of the upper aerodigestive tract—with direct care
costs of ≈£32,000 per patient [20] and a significant mor-
bidity for the patients involved. There are national guide-
lines recommending that the proportion of HNSCC
patients treated by intensity modulated radiation therapy
(IMRT) be increased [21]. However, with respect to swal-
lowing outcomes, IMRT has been shown to increase stric-
ture rates 3.3 times [22]; up to 46 % of HNSCC patients
treated by IMRT may needed oesophageal dilatation [23],
an intervention that needs inpatient care, is distressing to
the patient and is associated with complications.
A systematic review [15] has suggested that feeding
route during treatment may impact on the swallow per-
formance after CRT. Four retrospective studies [24–27]
one prospective study [28] and one randomised con-
trolled trial (RCT) (with small patient numbers) [29]
have identified that swallowing difficulties are more
prevalent in patients receiving a prophylactic G-tube,
even in the long term. However, existing research on the
association of early G-tube feeding and long-term swal-
low impairment has been inconclusive due to small par-
ticipant numbers, by the use of insensitive dysphagia
measurements and by limited long-term follow-up. The
sole RCT [29] recruited from a single Australian centre
in an area of low population density. A Cochrane review
[14] identified no further eligible trials and concluded
that there was insufficient evidence to determine the op-
timal method of enteral feeding for patients with
HNSCC receiving RT or CRT.
These two methods have never been properly compared
to establish which leads to better outcomes for patients,
despite calls for better information to guide patient and
clinician decisions [14, 24, 29]. We therefore wish to con-
duct a RCT to compare the two feeding methods (pre-
treatment gastrostomy versus oral feeding plus as-needed
nasogastric tube) in patients with no or only minimal
swallowing problems. A similar trial in Australia [29]
failed to recruit enough patients; hence, we wish to first
carry out a feasibility study to see whether a RCT is pos-
sible and inform how it should be conducted.
Methods/design
Aims and objectives
Our aim is to determine whether a definitive RCT is
feasible in head and neck cancer patients with minimal
swallowing problems undergoing CRT comparing oral
feeding plus prophylactic gastrostomy tube feeding ver-
sus oral feeding plus as-needed nasogastric tube feeding
(TUBE study). The TUBE study feasibility phase is a ne-
cessary prelude to a full trial of these complex interven-
tions, to assess (i) whether an adequate proportion of
eligible patients can be recruited into the study and (ii)
whether an adequate proportion of patients comply with
the trial protocol including outcome measure comple-
tion, according to both quantitative and qualitative data.
The objectives are:
A. To explore barriers and facilitators to trial
implementation and to use this information to
improve recruitment and retention
1. Willingness of participants to be randomised, to
accept and persist with allocated treatment and
comply with assessments.
2. Willingness of clinicians (including clinical
oncologists, surgeons, nutritionists, speech and
language therapists) to recruit patients.
3. Qualitative assessment of patient and carer
perspectives on trial participation, barriers to
randomisation among non-participants, acceptability
of assessment tools and experience of the tube
feeding, conduct and compliance of the trial
protocol and reasons (and characteristics) of patients
dropping out.
B. To carry out preliminary estimation of key
parameters to inform definitive study design and
study processes
1. Confirm primary outcome measure and
associated power/sample size for definitive trial:
dysphagia related quality of life as measured by
MD Anderson Dysphagia Inventory (MDADI)
HNSCC-specific self report scale (variation and
differences in change from baseline at 6 months).
2. Trial our subsidiary QoL outcomes (the European
Organization for Research and Treatment of
Cancer questionnaires EORTC QLQ-C30,
EORTC QLQ - H&N35), short form 36 (SF-36) a
multi-purpose, short-form health survey and data
collection tools for use of health and personal
social services and patient costs.
3. Monitor nutritional parameters: body mass index,
weekly weight changes (during treatment) and
quantity of enteral nutrition consumed.
4. Derivation of an algorithm for when NG tube
should be placed in the oral intake arm that is
acceptable to patients and nutritionists.
C. Provide health economics metrics
1. Assess economic value of information based upon
a modelling exercise informed by the feasibility
study and the existing systematic reviews.
2. Provide preliminary estimate of the costs, effects
and relative cost-effectiveness of the alternative
methods of nutritional support based upon the
modelling exercise.
Design
A mixed methods multicentre study to establish the feasi-
bility of a RCT of feeding methods in patients with stages
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III and IV head and neck cancer receiving CRT with cura-
tive intent. The work will be conducted over 24 months.
The components are:
1. A multicentre randomised controlled pilot feasibility
trial comparing oral feeding plus pre-treatment
gastrostomy versus oral feeding plus as required
nasogastric tube feeding in patients with HNSCC.
Patients will be randomised on a 1:1 basis and
stratified by IMRT and by the treating centre.
2. A qualitative process evaluation to inform the trial
design by investigating patient, carer and staff
experiences of trial participation.
3. A modelling exercise to synthesise available evidence
and provide preliminary estimates of cost-
effectiveness and value of information from future
research.
Setting
The setting was five tertiary NHS centres for HNSCC.
For our definitive trial, additional centres will be re-
cruited via our links with the National Cancer Research
Network, Comprehensive Clinical Research Network
and from respondents to our national survey [16].
Ethical considerations
Ethical approval was sought and granted by the Newcastle
and North Tyneside 2 Committee, NHS Health Research
Authority, reference 14/NE/0045.
Target population
The target population will be patients with stage III and
IV HNSCC who receive primary CRT with curative intent.
Inclusion criteria:
(1) Grade 1 pre-treatment dysphagia, as defined by
Common Terminology Criteria for Adverse Events v4.0
(defined as asymptomatic/symptomatic/able to eat regu-
lar diet). (2) Consent to be randomised.
Exclusion criteria:
Patients who (1) decline to participate, (2) are unable
to give informed consent, (3) cannot receive a gastros-
tomy for medical reasons, (4) do not receive treatment
with curative intent and (5) patients with malnutrition
requiring immediate initiation of enteral feeding.
Clinical experience suggests that patients with primary
sites in the oropharynx, larynx, nasopharynx and un-
known primaries are those who will fulfil the inclusion
criteria (~35 to 40 % of all HNSCC patients).
Interventions
Pre-CRT gastrostomy arm: endoscopic or radiologic gas-
trostomy will be placed before commencement of CRT.
Given the pragmatic nature of this study and equivalent
success rates with either technique, the choice of method
of insertion will be left to local protocols of the treating
centre. Patients will continue with oral feeding and com-
mence use liquid nutrition through the G tube when they
are unable to maintain an adequate oral intake to meet
their nutritional requirements (<75 % of requirements
based on a dietetic assessment of 24-h recall by patients).
No pre-CRT gastrostomy arm: this group will continue
with oral feeding or have a nasogastric tube if required
during treatment. The decision to place a nasogastric
tube will be based on clinical assessment, patient request
and published guidelines [6], patient request for gastros-
tomy tube may also lead to gastrostomy placement.
Based on published prospective data, we anticipate that
<10 % will convert from NG tube to G tube during the
study.
Outcomes measures
The primary outcome of feasibility will comprise of the
following entities:
1. Willingness of patients to be randomised (assessed
via review of patient screening logs) defined as:
i. The number of patients consenting to be
randomised as a proportion of all patients
approached about the trial, with reasons for
non-consent
ii. Qualitative assessment of barriers and facilitators
to recruitment
2. Willingness of clinicians to randomise
patients—assessed via qualitative interviews
3. Assessment of retention and drop-out rates, defined as:
i. The number of patients who start randomised
treatment as a proportion of the number
randomised, with reasons for early drop outs
ii. The number of patients who complete
randomised treatment as a proportion of the
number randomised, with reasons for drop outs
(including death)
iii. Completeness of MD Anderson Dysphagia
Inventory (MDADI) assessment within 6 months
iv. Qualitative assessment of barriers and facilitators
to data collection and participant retention
Secondary outcome measures are:
The following scores/ measures will be requested at
baseline (before treatment) and at 3 and 6 months after
treatment (5 and 8 months from randomisation):
A. The MDADI is a self-administered questionnaire
designed specifically for evaluating the impact of
dysphagia on the quality of life of patients with head
and neck cancers [30]. This will be our primary
outcome measure in the full trial.
B. Quality-of-life outcomes
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We will use two questionnaires to assess quality of life
outcomes. The European Organization for Research and
Treatment of Cancer questionnaire EORTC QLQ-C30
(version 3.0) is a cancer-specific instrument, has a multidi-
mensional structure, appropriate for self-administration
and is applicable across a range of cultural settings [31].
The EORTC QLQ - H&N35 is the head and neck module
for EORTC QLQ-C30 (version 3.0) and is intended for
use in conjunction with the QLQ-C30 in patients with
head and neck cancer [32].
C. Short form 36
The SF-36 is a multi-purpose, short-form health sur-
vey with 36 questions. It yields an eight-scale profile of
functional health and well-being scores as well as psy-
chometrically based physical and mental health sum-
mary measures and a preference-based health utility
index that will be used to derive quality-adjusted life-
years for a cost-utility analysis conducted as part of a
subsequent full trial.
D. Use of health and personal social services and costs
to patients and their families/carers
For the definitive economic evaluation costs to pa-
tients and their families/carers, the NHS and per-
sonal social services will be elicited. Within the
feasibility study, we will develop the tools necessary
to elicit these costs. Specifically, we will develop case
report forms and questionnaires to capture use of
services and patient/family/carer costs. The content
of these forms will be developed in consultation with
the study team, our existing item bank of questions,
web based resources e.g. www.dirum.org and experi-
ence from other RCTs of nutritional interventions
e.g. the recent SIGNET trial [33]. The tool devel-
oped will be administered at 3 and 6 months after
treatment.
E. Nutritional parameters
We will measure the body mass index before treatment,
at 3 months and at 6 months following treatment. We will
also measure weekly weight changes during treatment and
the quantity of enteral nutrition consumed.
F. Oral health monitoring
We will perform oral health assessment before com-
mencing treatment and the end of 6 months for all den-
tate patients. A full dental chart with panaromic
radiographs will be performed at pre-treatment and at
6 months. Periodontal and oral hygiene assessment and
plaque scores will also form part of this assessment and
be documented.
Statistical considerations
Target recruitment is 60 patients (30 per arm of the
study) [34]. As a feasibility study, we will provide an as-
sessment of recruitment and compliance rates to inform
future trial design. Statistical analyses are according to a
confidence interval rather than a hypothesis testing ap-
proach. Analyses will be descriptive reporting rates as
proportions with confidence intervals and graphical ana-
lyses of longitudinal data. Recruitment is dependent on
the number of patients approached but should be no
lower than 50 %. The upper limit of the 95 % confidence
interval for the proportion of patients recruited should
exceed 50 %. If 120 patients were approached and 50 %
were recruited (60 patients randomised), the 95 % confi-
dence interval for the recruitment rate would have width
±9 %. This would provide a good level of accuracy to as-
sess the acceptability of the recruitment rate.
Progression criteria to phase III trial
The decision to move to a phase III trial will be based on:
1. Adequate timely recruitment with a 50 %
recruitment rate.
2. Completeness of outcome measurement (MDADI at
6 months): excluding those individuals who die
during the study period. This outcome data
successfully collected should be greater than or
equal to 80 %, as this will be the primary outcome
for the planned phase III trial.
3. Economic criteria of EVOI to suggest further
research likely to be worthwhile.
Qualitative process evaluation
The integrated qualitative process evaluation will explore
barriers and facilitators to trial implementation. Through
regular feedback of emerging findings to the trial team it
will inform the day-to-day running of the pilot trial and
optimise recruitment and retention. It will also identify
aspects of trial processes which could be improved for
the definitive trial.
A. Normalisation process theory
Our analysis of facilitators and barriers to trial partici-
pation will be informed by normalisation process theory
[35]. Normalisation process theory considers factors that
affect implementation in relation to four key areas; how
people make sense of a new practice (in this case—the
trial) (coherence); the willingness of people to sign-up
and commit to the new practice (cognitive participation);
their ability to take on the work required of the practice
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(collective action); and activity undertaken to monitor
and review the practice (reflexive monitoring). This theory
is increasingly being used in studies of the implementation
of interventions in health care (www.normalizationproces-
s.org). In the current study, we will consider how well trial
processes are introduced and incorporated at each site for
both patient and professional groups.
B. Methods and sampling
Numbers have been included to give an indication of
the amount of data to be collected. We have given par-
ticular thought, for example, to whether there might be
significant subgroups of patients or professionals, which
would require an additional layer of data collection and
analysis. However, in keeping with the principles of
rigorous qualitative research, the actual sample size will
be informed by the point of data saturation; we will be
responsive to the study context and anticipate that in
some cases, fewer interviews or observations will be
conducted, and in others, additional data will be col-
lected in response to our emerging analysis or study
events. We aim to achieve a balance between spread of
data (to avoid missing key events or issues) and depth (a
manageable data set that allows for in-depth analysis);
having the flexibility to identify and focus in on those is-
sues which our analysis suggests is key to successful
study implementation.
Data collection will focus on three inter-related
phases over the duration of the trial Following appro-
priate consent, we will include interviews with health
professionals (n = 15–24); patients (n = 32–36); observa-
tion of recruitment discussions (n = 9–18); and observa-
tions of multidisciplinary team meetings (n = 6–15);
details below.
Pre-implementation of TUBE pilot trial In order to
understand the context, professionals’ views and expecta-
tions and to map patient pathways, we will visit each study
site. We will conduct formal interviews with key individ-
uals (n = 2–3 per site) involved in treatment planning for
HNSCC (e.g. nurses; speech therapists; ENT surgeons).
Patient recruitment phase We will focus on patients’
and professionals’ experiences of recruitment. Patients
will be recruited from multidisciplinary clinics, with trial
information being provided by research nurses. We will
conduct qualitative interviews with patients who have
consented to take part in the trial (n = 5 in the G-tube
group; n = 5 in oral feeding group) and where possible,
those that decline to take part either at recruitment or
who withdraw at the point of randomisation (n = 10).
We will focus on their experiences and understandings
of trial processes (e.g. the information they were given;
the recruitment encounter; their ideas and/or concerns
about randomisation and consent) and the intervention
(willingness to undergo either feeding option; ideas and/
or concerns about impact on health and acceptability).
Ideally, we would interview patients within 2 weeks of re-
cruitment discussions. Patients will be offered a choice of
location and method (telephone; face-to-face) of interview.
We know that individuals often discuss clinical decisions
with other people [36] so patients who wish to involve a
family member in their interview will be able to do so.
We will also conduct further interviews with profes-
sionals involved in some aspect of patient recruitment
(n = 3–5 per site) and, where possible, observe multidis-
ciplinary team meetings to understand the process of
identification of eligible patients (n = 1–3 per site).
Again, where possible, study recruitment discussions
(either at treatment planning clinic or subsequent dis-
cussion with clinical nurse specialist) will, with consent,
be observed (n = 3–6 per site). An initial visit to each site
will take place shortly after (1–2 months) the site com-
mences patient recruitment. The timing of subsequent
visits to a site will be driven by factors such as variation
in recruitment rates between sites or changes in key
personnel.
Patient follow-up phase
We will also investigate patients’ (and carers’) experi-
ences of the tube feeding and trial participation through
qualitative interviews (n = 12–16) at approximately
8 months after recruitment, in order to explore the ac-
ceptability of assessment tools and their experiences of
the intervention. Where possible, the follow-up inter-
views will include second interviews with patients and
family members (or friends) interviewed at the recruit-
ment phase; additional participants will be recruited
based on emergent criteria (e.g. length of time of oral
and/or supplementary feeding).
C. Qualitative data management and analysis
Interviews and recruitment discussions will, with con-
sent, be audio-recorded, transcribed verbatim and edited
to ensure anonymity of respondent. Data will be managed
using NVivo software. The analysis will be theoretically-
informed by normalisation process theory and will be con-
ducted according to the standard procedures of rigorous
qualitative analysis [37] including open and focused cod-
ing, constant comparison, memoing [38], deviant case
analysis [39] and mapping [40]. We will undertake inde-
pendent coding and cross checking and a proportion of
data will be analysed collectively in ‘data clinics’ where the
research team share and exchange interpretations of key
issues emerging from the data.
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D. Relationship between process evaluation and pilot trial
Findings will be regularly fed back to the study team
and appropriate changes made to study processes during
the lifetime of the study. For example, if the pre-pilot work
identifies a problem with the coherence of the trial to one
group of professionals, then additional awareness raising/
education sessions or materials will be developed.
Economic modelling
The economic model will estimate the costs, effects and
relative cost-effectiveness of the alternative methods of
nutritional support. Data collection takes place during
the study and all analyses will be conducted by health
economists at the end of the study period. It will take
the perspective of the UK NHS and personal social ser-
vices (PSS). In the base case, all costs and effects will be
discounted at 3.5 % [41]. In addition, as described below,
the model will also estimate the expected value of infor-
mation and expected value of sampling information to
help inform the future definitive study.
The methods to paramaterise the model are described
below. To allow for uncertainty to be characterised around
these data—costs, effects and cost-effectiveness—and to en-
able the value of information analysis to be conducted a
probabilistic sensitivity analysis will be performed using
Monte Carlo simulation. All uncertainty surrounding esti-
mates of input parameters will be informed by appropriate
distributions. Modelling will conform to recommendations
for best practice including those developed for economic
evaluation models [42].
A. Structure of the economic model
Treatment pathways for patients undergoing chemora-
diation for HNSCC will be developed. The treatment
pathway will start with the choice of nutritional support.
These pathways will be based upon the material pre-
pared for the feasibility study and advice from the key
stakeholders involved in the study. Following recom-
mendations for best practice, these care pathways will be
used to develop a mathematical model covering the
period of initial intervention and the costs and conse-
quences of any subsequent outcomes including further
interventions.
B. Derivation of cost data
Information on the precise description of the resources
required for each intervention will be based upon data de-
rived from the feasibility study. From participants re-
cruited to the trial, we will estimate costs for each method
of nutritional support. Given the small study size, these
data will be imprecise and this imprecision will form a key
input into the analysis. Further cost data will be required
on subsequent management; these data will be identified
with the help of members of the study group and a search
of the economic literature. Unit costs will be taken from
appropriate routine sources e.g. NHS reference costs,
British National Formulary for drugs.
C. Derivation of utilities
For the cost-utility analysis, effects/benefits will be esti-
mated in quality-adjusted life-years. For each health state, a
health state utility will be defined. The data will be derived
from the pilot trial and a focused search to identify utility
data, including a search on the CEA Registry (https://
research.tufts-nemc.org/cear/default.aspx). The estimates
used within the model will be based upon the best available
data, ideally derived using SF-6D (as the SF-36 will be used
within the feasibility study and can be used to derive SF-6D
scores). Nevertheless, such data may not be readily identifi-
able and data from other sources along with judgements as
to how that measure compares to SF-6D scores will be
used.
D. Epidemiological and relative effectiveness data
The main source of evidence to inform the probabil-
ities required for the model will be the existing system-
atic reviews and other literature summarised in the
‘Background’ section of this application. From these
sources, information on the likelihood of key events
described in the economic model will be sought. Add-
itional focused searches will be conducted as necessary
to identify the best available evidence relevant to the UK
NHS for such probabilities.
E. Estimation of relative efficiency
The results of the economic model will be presented
as a cost-utility analysis (CUA). In the CUA, mean costs,
mean quality-adjusted life-years, incremental costs and
quality-adjusted life-years will be presented.
F. Uncertainty
It is possible that sufficient data to populate the
model will not be identified. In such a case, threshold
values will be explored where data is missing by vary-
ing estimates through a range thought plausible
(based on advice of the stakeholders involved in the
study). Within a probabilistic analysis, a plausible dis-
tribution will be assigned to this range (which may
include a uniform distribution to indicate that we do
not know what value a parameter might take within a
specified range).
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Deterministic sensitivity analyses will be carried out to
test for the effect of assumptions and variability [43] such
as the impact of changes in discount rates. The probabilis-
tic sensitivity analysis will also be undertaken for both the
base case analysis and, where sensible, all deterministic
sensitivity analyses allowing presentation of results in a
series of cost-effectiveness acceptability curves (CEAC).
Estimates of costs and quality-adjusted life-years will be
calculated as the expectation over the joint distribution of
the parameters. Relevant distributions will be informed by
the systematic reviews and meta-analyses, other literature
or expert opinion according to best practice [44].
G. Value of information analysis: Identification of future
research needs
We anticipate that the economic model will only provide
preliminary data on the relative effectiveness and cost-
effectiveness of the different methods of nutritional sup-
port. The main purpose of the model will be to help inform
decisions about the direction of future research. Within the
economic component of this study this will be explored
using variants of value of information analysis [45–48].
We will initially estimate the expected value of perfect
information and expected value of removing uncertainty
surrounding specific parameters or groups of parameters
to identify where further research should focus on identi-
fying more precise and reliable estimates of specific pieces
of information e.g. relative effectiveness, costs, utilities
(the expected value of partial perfect information). Ex-
pected value of perfect information and expected value of
partial perfect information can be interpreted as the value
of eliminating a wrong decision and it places an upper
value on conducting further research overall (expected
value of perfect information) or a specific area of informa-
tion (expected value of partial perfect information). Ex-
pected value of perfect information and expected value of
partial perfect information at an individual level can be es-
timated directly from the model but will need to be com-
bined with information on the number of people who
could benefit from the gastrostomy tube feeding over the
expected lifetime of the project. As these two factors are
uncertain sensitivity analysis will be used to explore alter-
native assumptions. If relatively small values are obtained
for expected value of perfect information and expected
value of partial perfect information (although we note that
this is a judgement), then this suggests that no further re-
search is necessary or no further research is required to
obtain ‘better’ estimates for specific groups of parameters.
A judgement will be formed based upon the findings the
expected value of perfect information analysis as to whether
a move to the analytically complex, expected value of sam-
pling information, will be made. Expected value of sampling
information provides further information on the value of
removing some of the existing uncertainty and also expli-
citly takes into account the cost of generating that future
research to estimate the expected net benefit of sampling.
Specifically, in this study, we will explore the use of this ap-
proach to identify, from an economic perspective, the opti-
mal trial design. Such methods have only very rarely been
used to determine the size of randomised controlled trials
and therefore following the recommendations of forthcom-
ing guidance the findings of this analysis will be used along
with other information to determine the sample size for the
trial [49].
Discussion
Potential impact of the trial
Our national survey [16] shows that clinicians working in
this field are in equipoise regarding the feeding route to
be used in patients receiving chemoradiation for head and
neck cancer. The survey concluded that in the absence of
a national consensus on which patients to recommend for
gastrostomy, consideration should be given to the devel-
opment of clinical decision-making models in an attempt
to systematise the decision-making process.
Clinicians have looked at this issue in a paper published
in 2001 [24], when a robust study was called for in this
field. Since then, Cochrane reviews [14] and other pro-
spective and retrospective studies [25, 27–29] have been
published, indicating that there is an appetite to progress
the science in this area. By using swallowing outcomes as
our primary measure, we are focusing on an outcome that
patients tell us as being important issue [18]. Thus, if this
trial finds evidence to support a change in clinical practice,
such findings will have the required impact. It is worth
noting that if the change in practice were to support the
non-surgical (oral + NG tube) arm, there may be reduc-
tions in morbidity and mortality caused by the interven-
tions. There may also be potential cost savings in the non-
surgical arm but this may be offset by the cost of repeat
return to hospital for re-siting NG tubes, radiologic exam-
inations, and the cost of district nursing support with NG
tubes which is not always required with G tubes. In
addition, some of the generic conclusions on the patient
and carer experiences of tube feeding will be applicable to
other areas of medicine. Thus, research on this area may
serve to direct resources appropriately, reduce unneces-
sary interventions and thus reduce morbidity, mortality
and improving swallowing outcomes. Irrespective of the
effect size the TUBE study demonstrates, the project will
generate a great deal of invaluable comparator informa-
tion about the two treatments which can inform patient
contribution to future shared decision-making. Our inte-
grated qualitative study will draw on the theoretical frame-
work of normalisation process theory [35] to identify the
barriers and facilitators to changing clinical practice in this
field.
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Trial status
Currently recruiting/in-patient follow-up.
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